Revises provisions relating to pharmacy benefit managers. (BDR 57-534)
SB209 substantially revises Nevada’s pharmacy benefit manager (PBM) laws and expands them to cover not only prescription drug benefits, but also pharmacist services. It broadens the statutory definition of a pharmacy benefits plan, adds new definitions for affiliated and nonaffiliated pharmacies, rebates, spread pricing, network plans, and related terms, and applies the new framework to PBMs operating in the state. The bill also extends certain requirements to ERISA-regulated plans to the extent allowed by federal law and removes a prior exemption for some employer-sponsored coverage.
The bill prohibits a PBM from steering patients to affiliated pharmacies when nonaffiliated pharmacies are available in the network, from discriminating against nonaffiliated pharmacies, and from using spread pricing. It also bars exclusive drug coverage arrangements with manufacturers and false or misleading statements or advertising. PBMs would have to disclose fees, commissions, and rebates to contracting third parties, pass rebate amounts through in a specified order, and file detailed annual reports with the Commissioner of Insurance. The Commissioner would then compile a biennial public report on PBMs’ overall impact on prescription drug costs in Nevada.
SB209 also changes how rebate money is handled by insurers and other health coverage entities. Insurers, carriers, societies, hospital and medical services corporations, health maintenance organizations, prepaid limited health service organizations, and managed care organizations that receive rebate money from PBMs would be required to use those funds only to reduce premiums or lower insureds’ cost-sharing obligations, with Medicaid-related managed care arrangements generally exempted. The bill authorizes the Commissioner to suspend or revoke certificates of authority for certain noncompliant entities and creates a private cause of action for pharmacies that face retaliation from a PBM, including statutory damages and attorney’s fees.
The overall sentiment reflected by the bill text is strongly consumer- and pharmacy-protective, with an apparent policy goal of increasing transparency, limiting PBM market power, and ensuring that rebates benefit patients rather than intermediaries. Because no committee transcripts or recorded votes were provided, there is no documented public debate in the supplied materials to indicate support or opposition. The bill’s structure suggests it is intended as a comprehensive regulatory reform measure rather than a narrow technical update.
The main points of contention likely center on the breadth of the new restrictions, the reporting burden on PBMs, the limits on contractual freedom, and the potential cost or administrative impact on insurers, PBMs, and local governments. The bill also contains an unfunded mandate and notes possible fiscal impact, which may raise concerns about implementation costs, confidentiality of business information, and whether the state’s requirements are fully preempted or limited by federal ERISA law.
SB209 would amend multiple chapters of Nevada law governing insurance, health maintenance organizations, managed care organizations, and public employee/local government health coverage. It would expand the regulatory scope of PBM law, impose new conduct restrictions and disclosure obligations, require rebate pass-through and rebate-use rules for insurers and other coverage entities, create reporting duties for PBMs and the Commissioner of Insurance, and authorize enforcement actions and penalties. It also makes conforming changes to public records law and local government insurance provisions, and delays most operative provisions until January 1, 2026, while allowing preparatory rulemaking to begin upon passage.
Based on the bill text alone, the measure appears to have a generally reform-oriented, pro-consumer, and pro-independent-pharmacy policy direction. It is designed to curb PBM practices viewed as anti-competitive or opaque and to ensure rebates reduce premiums and out-of-pocket costs. No committee transcript or vote history was provided, so there is no direct evidence of legislative support, opposition, or amendments in the supplied record.
Likely areas of contention include the prohibition on spread pricing, limits on affiliated-pharmacy steering, mandatory rebate pass-through, and the extensive annual reporting requirements, all of which could be opposed by PBMs, insurers, and affiliated pharmacy interests as burdensome or intrusive. The bill’s application to ERISA-related coverage to the extent permitted by federal law may also raise preemption concerns. In addition, the unfunded mandate and possible fiscal impact could concern local governments and regulated entities that would need to implement new compliance systems.